文献速递甲状腺疾病

男性并非术后甲状腺癌患者预后不良的危险因素:一项倾向性评分匹配研究

Male Sex Is Not a Risk Factor for Prognosis in Postoperative Thyroid Cancer Patients: A Propensity Score Matching Study.
PubMed 文献 · J Clin Endocrinol Metab · 2023-01-01

该回顾性研究纳入2016年4月至2021年10月接受131I治疗的1948例术后分化型甲状腺癌患者,男性645例、女性1303例,采用倾向性评分匹配(PSM)处理数据。PSM前男性预后不良比例显著高于女性,PSM后男女组预后不良比例无差异;PSM后男性不再是预后不良的危险因素,而高T分期(T3+T4)、M1期、sTg≥10.15 ng/mL和131I剂量≥260 mCi仍是危险因素。

要点

  • PSM前男性预后不良比例显著高于女性,PSM后男女组预后不良比例无差异。
  • PSM后男性不再是预后不良危险因素,高T分期、M1期、高sTg和高131I剂量仍是。
  • PSM后预后不良危险因素包括T3+T4期、M1期、sTg≥10.15 ng/mL和131I剂量≥260 mCi。

核心结论

  • 经PSM减少选择偏倚后,男性不再是分化型甲状腺癌131I治疗后的预后危险因素。
  • 高T分期(T3+T4期)、M1期、sTg≥10.15 ng/mL和131I剂量≥260 mCi是预后不良的危险因素。

研究设计与样本

  • 回顾性纳入2016年4月至2021年10月接受131I治疗的术后分化型甲状腺癌患者1948例,年龄43(四分位距:34,54)岁,分为男性组(n=645)和女性组(n=1303)。
  • 采用倾向性评分匹配(PSM)处理所有数据以减少数据偏倚和混杂变量的影响。
  • 使用Mann-Whitney U检验和χ2检验进行数据分析,多因素logistic回归分析影响预后的危险因素,受试者工作特征曲线分析sTg水平、131I剂量与不良预后之间的关系。

主要发现

  • PSM前男性预后不良比例显著高于女性;PSM后男女组预后不良比例无差异。
  • PSM前多因素logistic回归显示男性、高T分期、N1b期、M1期、高sTg水平和高131I剂量是预后不良的危险因素。
  • PSM后高T分期、M1期、高sTg水平和131I剂量仍是危险因素,但男性不再是预后不良的危险因素。

关键数值与推荐

  • PSM后预后不良危险因素包括高T分期(T3+T4期)、M1期、sTg≥10.15 ng/mL和131I剂量≥260 mCi。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To study whether male sex is a risk factor for prognosis in patients with differentiated thyroid cancer after 131I treatment using the propensity score matching (PSM) method. METHODS: From April 2016 to October 2021, 1948 postoperative differentiated thyroid cancer patients aged 43 (interquartile range: 34, 54) years who received 131I treatment were retrospectively enrolled and divided into male (n = 645) and female groups (n = 1303). The PSM method was adopted to process all data to reduce the influence of data bias and confounding variables. The Mann-Whitney U test and χ2 test were used for data analysis. Multivariate logistic regression was used to analyze the risk factors affecting prognosis, and the receiver operating characteristic curve was used to analyze the relationship between stimulated thyroglobulin (sTg) level, 131I dose, and poor prognosis. RESULTS: Before PSM, the proportion of male patients with poor prognosis was significantly higher than that of female patients. After PSM, there was no difference in the proportion of poor prognosis between male and female groups. Multivariate logistic regression analysis showed that male sex; high T stage, N1b stage, and M1 stage; high sTg level; and high 131I dose were risk factors for poor prognosis before PSM. After PSM, high T stage, M1 stage, high sTg level, and 131I dose were still risk factors but male sex was no longer a risk factor for poor prognosis. CONCLUSIONS: After the reduction of selection bias by PSM, male sex was no longer a risk factor for prognosis after 131I treatment of differentiated thyroid cancer. In addition, high T stage (T3 + T4 stage), M1 stage, sTg ≥10.15 ng/mL, and 131I dose ≥260 mCi were risk factors for poor prognosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Zhou Y, Wang Y, Zhang Z, et al. Male Sex Is Not a Risk Factor for Prognosis in Postoperative Thyroid Cancer Patients: A Propensity Score Matching Study. J Clin Endocrinol Metab. 2023. PMID: 37267432. doi:10.1210/clinem/dgad314

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。